US20110091466A1 - IgE ANTIBODIES FOR THE TREATMENT OF CANCER - Google Patents

IgE ANTIBODIES FOR THE TREATMENT OF CANCER Download PDF

Info

Publication number
US20110091466A1
US20110091466A1 US12/900,256 US90025610A US2011091466A1 US 20110091466 A1 US20110091466 A1 US 20110091466A1 US 90025610 A US90025610 A US 90025610A US 2011091466 A1 US2011091466 A1 US 2011091466A1
Authority
US
United States
Prior art keywords
ige
antibody
antigen
psa
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/900,256
Other languages
English (en)
Inventor
Manuel L. Penichet
Birgit C. Schultes
Christopher F. Nicodemus
Tracy R. Daniels
Gustavo Helguera
Jose A. Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Advanced Immune Therapeutics Inc
Original Assignee
University of California
Advanced Immune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Advanced Immune Therapeutics Inc filed Critical University of California
Priority to US12/900,256 priority Critical patent/US20110091466A1/en
Assigned to ADVANCED IMMUNE THERAPEUTICS, INC. reassignment ADVANCED IMMUNE THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NICODEMUS, CHRISTOPHER F., SCHULTES, BIRGIT
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA reassignment THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HELGUERA, GUSTAVO, RODRIGUEZ, JOSE A., DANIELS, TRACY R., PENICHET, MANUEL L.
Publication of US20110091466A1 publication Critical patent/US20110091466A1/en
Priority to US13/372,557 priority patent/US8697079B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF CALIFORNIA LOS ANGELES
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF CALIFORNIA LOS ANGELES
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US12/900,256 2008-04-09 2010-10-07 IgE ANTIBODIES FOR THE TREATMENT OF CANCER Abandoned US20110091466A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/900,256 US20110091466A1 (en) 2008-04-09 2010-10-07 IgE ANTIBODIES FOR THE TREATMENT OF CANCER
US13/372,557 US8697079B2 (en) 2008-04-09 2012-02-14 IgE antibodies for the treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4368208P 2008-04-09 2008-04-09
US4457608P 2008-04-14 2008-04-14
US15906909P 2009-03-10 2009-03-10
PCT/US2009/040085 WO2009126817A2 (fr) 2008-04-09 2009-04-09 Anticorps d'ige pour le traitement du cancer
US12/900,256 US20110091466A1 (en) 2008-04-09 2010-10-07 IgE ANTIBODIES FOR THE TREATMENT OF CANCER

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/040085 Continuation WO2009126817A2 (fr) 2008-04-09 2009-04-09 Anticorps d'ige pour le traitement du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/372,557 Continuation US8697079B2 (en) 2008-04-09 2012-02-14 IgE antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
US20110091466A1 true US20110091466A1 (en) 2011-04-21

Family

ID=41162615

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/900,256 Abandoned US20110091466A1 (en) 2008-04-09 2010-10-07 IgE ANTIBODIES FOR THE TREATMENT OF CANCER
US13/372,557 Active US8697079B2 (en) 2008-04-09 2012-02-14 IgE antibodies for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/372,557 Active US8697079B2 (en) 2008-04-09 2012-02-14 IgE antibodies for the treatment of cancer

Country Status (3)

Country Link
US (2) US20110091466A1 (fr)
EP (1) EP2331130B1 (fr)
WO (1) WO2009126817A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017734A1 (fr) * 2013-07-31 2015-02-05 Board Of Trustees Of The University Of Arkansas Compositions et méthodes permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
JP6156604B1 (ja) * 2015-09-03 2017-07-05 小野薬品工業株式会社 Ａｌｌｅｒｇｉｎ−１アンタゴニストによるがん免疫増強剤
US10908168B2 (en) 2017-01-31 2021-02-02 Vanderbilt University Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
US20220267423A1 (en) * 2021-02-22 2022-08-25 IgGenix, Inc. Ige antibodies cross-reactive to allergens and tumor antigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689355B2 (en) * 2000-05-11 2004-02-10 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
US6881405B2 (en) * 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083709A (en) * 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
GB9027767D0 (en) * 1990-12-21 1991-02-13 Cambridge Antibody Tech Binding substances
WO2008091643A2 (fr) * 2007-01-23 2008-07-31 Altarex Medical Corp. Système de culture in vitro pour évaluer la synergie du ciblage de voies immunosuppressives concomitantes à une immunothérapie
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US6881405B2 (en) * 1998-06-15 2005-04-19 Altarex Medical Corp. Reagents and methods for inducing an immune response to prostate specific antigen
US6689355B2 (en) * 2000-05-11 2004-02-10 Altarex Corp. Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017734A1 (fr) * 2013-07-31 2015-02-05 Board Of Trustees Of The University Of Arkansas Compositions et méthodes permettant de traiter et de prévenir le cancer par ciblage des antigènes glucidiques associés à la tumeur
CN113372450A (zh) * 2020-03-10 2021-09-10 北京万华生物工程有限公司 IgE嵌合性双特异性抗体制备及应用

Also Published As

Publication number Publication date
US20130022614A1 (en) 2013-01-24
EP2331130A2 (fr) 2011-06-15
EP2331130A4 (fr) 2012-11-07
WO2009126817A2 (fr) 2009-10-15
US8697079B2 (en) 2014-04-15
EP2331130B1 (fr) 2018-02-14
WO2009126817A3 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
JP6931329B2 (ja) 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11498972B2 (en) Anti-OX40 antibody and use thereof
JP7325959B2 (ja) 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体
WO2020098734A1 (fr) Anticorps anti-tigit et son utilisation
JP7341217B2 (ja) 抗ｃｄ１３７抗体
EP4353745A1 (fr) Groupe d'anticorps monoclonaux anti-b7h3 et son utilisation médicale
US8697079B2 (en) IgE antibodies for the treatment of cancer
JPH09501824A (ja) モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質
CA2259371A1 (fr) Composes therapeutiques a specificite multiple consistant en anticorps anti-recepteurs du fc.alpha.
WO2019141092A1 (fr) Anticorps anti-lag-3 et son utilisation
CN107949571A (zh) 调控免疫反应的方法及抗体
US20210355228A1 (en) Fc binding fragments comprising an ox40 antigen-binding site
JP2020503860A (ja) 免疫応答のコンディショナルアゴニスト
US20220119539A9 (en) Fc binding fragments comprising a cd137 antigen-binding site
US8945566B2 (en) Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of disease
WO2021115404A1 (fr) Anticorps anti-cd38 et son utilisation
CN110382541A (zh) 人源化抗cd40抗体
US20220378876A1 (en) Treatment Involving Therapeutic Antibody and Interleukin-2 (IL2)
WO2022184155A1 (fr) Anticorps anti-ctla-4 et son utilisation
WO2024040149A2 (fr) Anticorps cd20 dérivés de poulet ayant une activité de déplétion de cellule b puissante
TW202334221A (zh) 雙特異性cd16a結合劑
JP2010514434A (ja) ヒトｌｄｌ受容体に対するモノクローナル抗体

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADVANCED IMMUNE THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHULTES, BIRGIT;NICODEMUS, CHRISTOPHER F.;SIGNING DATES FROM 20101115 TO 20101116;REEL/FRAME:025512/0613

AS Assignment

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PENICHET, MANUEL L.;DANIELS, TRACY R.;HELGUERA, GUSTAVO;AND OTHERS;SIGNING DATES FROM 20101214 TO 20101223;REEL/FRAME:025593/0968

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA LOS ANGELES;REEL/FRAME:030756/0222

Effective date: 20130702

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CALIFORNIA LOS ANGELES;REEL/FRAME:041477/0857

Effective date: 20170306